Shots:

• Under Dzuveo agreement- AcelRx to receive ~$55M as an up front and commercial milestones in addition to 35% to 45% revenue share on net sales of Dzuveo. AcelRx will manufacture and supply Dzuveo while Aguettant gets the right to commercialize Dzuveo in the EU
• As per second agreement- Aguettant has the right to receive ~$24M as commercial milestone at ~$60M annual sales levels in addition to 40 to 45% revenue share on net sales of the two pre-filled syringe products- following their approval in the US
• AcelRx obtains the rights to file NDAs and commercialize two pre-filled syringe product in the US

  Ref: PR Newswire | Image: PR Newswire